Switch theme
Sign up to access all valuation multiples
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
2009
619
LTM Revenue $189M
LTM EBITDA -$70.3M
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Adaptive Biotech has a last 12-month revenue of $189M and a last 12-month EBITDA of -$70.3M.
In the most recent fiscal year, Adaptive Biotech achieved revenue of $179M and an EBITDA of -$129M.
Adaptive Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Adaptive Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $170M | $179M | XXX | XXX | XXX |
| Gross Profit | $127M | $94.7M | XXX | XXX | XXX |
| Gross Margin | 75% | 53% | XXX | XXX | XXX |
| EBITDA | -$189M | -$129M | XXX | XXX | XXX |
| EBITDA Margin | -111% | -72% | XXX | XXX | XXX |
| Net Profit | -$200M | -$225M | XXX | XXX | XXX |
| Net Margin | -118% | -126% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Adaptive Biotech's stock price is $8.
Adaptive Biotech has current market cap of $1.2B, and EV of $1.0B.
See Adaptive Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $1.2B | XXX | XXX | XXX | XXX | $-1.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Adaptive Biotech has market cap of $1.2B and EV of $1.0B.
Adaptive Biotech's trades at 5.5x LTM EV/Revenue multiple, and -14.6x LTM EBITDA.
Analysts estimate Adaptive Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Adaptive Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.0B | XXX | XXX | XXX |
| EV/Revenue | 5.8x | XXX | XXX | XXX |
| EV/EBITDA | -8.0x | XXX | XXX | XXX |
| P/E | -7.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -10.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAdaptive Biotech's NTM/LTM revenue growth is 20%
Adaptive Biotech's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Adaptive Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Adaptive Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Adaptive Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -72% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -32% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -52% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 47% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 41% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 58% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 147% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adaptive Biotech acquired XXX companies to date.
Last acquisition by Adaptive Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Adaptive Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Adaptive Biotech founded? | Adaptive Biotech was founded in 2009. |
| Where is Adaptive Biotech headquartered? | Adaptive Biotech is headquartered in United States of America. |
| How many employees does Adaptive Biotech have? | As of today, Adaptive Biotech has 619 employees. |
| Who is the CEO of Adaptive Biotech? | Adaptive Biotech's CEO is Mr. Chad M. Robins. |
| Is Adaptive Biotech publicy listed? | Yes, Adaptive Biotech is a public company listed on NAS. |
| What is the stock symbol of Adaptive Biotech? | Adaptive Biotech trades under ADPT ticker. |
| When did Adaptive Biotech go public? | Adaptive Biotech went public in 2019. |
| Who are competitors of Adaptive Biotech? | Similar companies to Adaptive Biotech include e.g. Zomedica, AnteoTech, Proteomics International, Biohit. |
| What is the current market cap of Adaptive Biotech? | Adaptive Biotech's current market cap is $1.2B |
| What is the current revenue of Adaptive Biotech? | Adaptive Biotech's last 12-month revenue is $189M. |
| What is the current EBITDA of Adaptive Biotech? | Adaptive Biotech's last 12-month EBITDA is -$70.3M. |
| What is the current EV/Revenue multiple of Adaptive Biotech? | Current revenue multiple of Adaptive Biotech is 5.5x. |
| What is the current EV/EBITDA multiple of Adaptive Biotech? | Current EBITDA multiple of Adaptive Biotech is -14.6x. |
| What is the current revenue growth of Adaptive Biotech? | Adaptive Biotech revenue growth between 2023 and 2024 was 5%. |
| Is Adaptive Biotech profitable? | Yes, Adaptive Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
